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ABSTRACT
With its high efficiency for site-specific genome editing
and easy manipulation, the clustered regularly inter-
spaced short palindromic repeats (CRISPR)/ CRISPR
associated protein 9 (CAS9) system has become the
most widely used gene editing technology in biomedical
research. In addition, significant progress has been
made for the clinical development of CRISPR/CAS9
based gene therapies of human diseases, several of
which are entering clinical trials. Here we report that
CAS9 protein can function as a genome mutator inde-
pendent of any exogenous guide RNA (gRNA) in human
cells, promoting genomic DNA double-stranded break
(DSB) damage and genomic instability. CAS9 interacts
with the KU86 subunit of the DNA-dependent protein
kinase (DNA-PK) complex and disrupts the interaction
between KU86 and its kinase subunit, leading to defec-
tive DNA-PK-dependent repair of DNA DSB damage via
non-homologous end-joining (NHEJ) pathway. XCAS9 is
a CAS9 variant with potentially higher fidelity and
broader compatibility, and dCAS9 is a CAS9 variant
without nuclease activity. We show that XCAS9 and
dCAS9 also interact with KU86 and disrupt DNA DSB
repair. Considering the critical roles of DNA-PK in
maintaining genomic stability and the pleiotropic impact
of DNA DSB damage responses on cellular proliferation
and survival, our findings caution the interpretation of
data involving CRISPR/CAS9-based gene editing and
raise serious safety concerns of CRISPR/CAS9 system
in clinical application.
KEYWORDS CAS9, DNA-PK, DNA double-stranded
breaks, genetic instability, DNA repair
INTRODUCTION
CAS9 is a type II DNA endonuclease widely used in genome
editing and epigenetic modification (Jinek et al., 2012; Cong
et al., 2013; Mali et al., 2013). CAS9 can efficiently target the
entire genomic DNA sequence using the Protospacer Adja-
cent Motif (PAM) domain and a guide RNA (gRNA) (Komor
et al., 2017; Murovec et al., 2017). In addition to its extensive
use in biomedical research, the clinical application of the
CRISPR/CAS9 system in human therapy has been inten-
sively investigated (Barrangou and Doudna, 2016; Dever
et al., 2016; Urnov, 2018; WareJoncas et al., 2018; Zhu
et al., 2019). Variants of CAS9 have also been developed for
distinct biological functions and improved editing fidelity. For
example, the nuclease dead-CAS9 (dCAS9) has been
developed for gene activation (Gilbert et al., 2013; Maeder
et al., 2013), RNA editing (Cpf1) (Zetsche et al., 2015), and
some smaller editing systems (Harrington et al., 2018).
However, a number of problems still challenge the broad
utility of CAS9 in research and clinical application (Tan et al.,
2015; Haapaniemi et al., 2018; Ihry et al., 2018). For
example, recent reports indicate that the combination
of CAS9 and gRNA introduces genomic DNA DSBs, leading
to p53-dependent cytotoxicity of human pluripotent stemShuxiang Xu, Jinchul Kim, and Qingshuang Tang have contributed
equally to this work.
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cells (Ihry et al., 2018). Using long-read sequencing,
researchers recently show that the genome editing mediated
by CRISPR/CAS9 and gRNA could lead to large DNA
deletions and complex rearrangements in the genome (Guo
et al., 2018; Kosicki et al., 2018; Lei et al., 2018).
DNA double-stand break (DSB) damage is the most
common genomic DNA lesion during cellular proliferation
and genome editing (Jackson and Bartek, 2009), which
could be repaired by two pathways: the direct DNA ligation of
the broken DNA ends termed NHEJ and homologous DNA
template guided homologous directed repair (HDR) (Mlade-
nov and Iliakis, 2011). Immediately after the introduction of
DSB, the DNA repair pathways are activated with a large
panel of proteins recruited to the site of DNA DSBs
(Mladenov and Iliakis, 2011). In the context of NHEJ, Ku70/
86 heterodimer bind to the DNA DSBs to stabilize the DNA
DSB ends and then recruit DNA dependent protein kinase
catalytic subunit (DNA-PKcs) to the site of DNA DSB (Davis
et al., 2014). DNA-PK complex is required for NHEJ by
recruiting and phosphorylating a panel of the DNA repair
factors including XRCC4 to facilitate DNA DSB repair (Ue-
matsu et al., 2007; Davis et al., 2014). We demonstrate that
CAS9 can disrupt the formation of DNA-PK complex through
the interaction with KU86, promoting DNA DSB damage.
RESULTS AND DISCUSSION
CAS9 induces DNA DSB damage in human cells
independent of gRNA
For the clinical application of any gene editing technology,
the genetically modified cells must maintain genomic sta-
bility. Because there is no reported study to investigate the
impact of CAS9 on the genomic stability in the absence of
gRNA, we used the doxycycline (Doxy) inducible expression
system to induce the expression of CAS9 in human embry-
onic stem cells (hESCs). The expression of CAS9 protein in
the absence of any exogenous gRNA activated DNA dam-
age responses, including the phosphorylation of p53 at
Ser15, CHK1 at Ser317, and H2AX at Ser139 (Fig. 1A).
Consistent with this finding, the expression of CAS9 protein
alone in hESCs was sufficient to induce the foci formation of
H2AX at Ser139 (γH2AX), a marker for DNA DSBs in the
genome (Fig. 1B). We used comet assay to confirm that the
expression of CAS9 protein alone in hESCs induced DNA
DSB damage (Fig. 1C). Nuclear fractionation analysis indi-
cated that CAS9 is present in both nucleus and cytoplasm
(Fig. 1D). Activation of p53 in hESCs can activate apoptosis
and differentiation of hESCs as previously shown (Lin et al.,
2005; Song et al., 2010). The DNA DSB damage induced by
CAS9 activated the expression of p53 target genes such
as PUMA, p21, PERP and NOXA, leading to the cell death
and differentiation of hESCs (Fig. 1E–G).
To confirm this genome mutator function of CAS9 in
mammalian cells, we employed the same CAS9 inducible
expression system to express CAS9 in human induced
pluripotent stem cells (hiPSCs) and human fibroblasts.
Consistent with the findings in hESCs, the expression of
CAS9 alone in hiPSCs and human fibroblasts was sufficient
to induce DNA DSB damage and activate DNA damage
responses (Figs. 2A and 3A–C). Using decreasing dosages
cFigure 1. The expression of CAS9 alone in hESCs
promotes DNA DSB damage and activates DNA dam-
age response pathway. (A) Inducible expression of CAS9
in hESCs activated DNA damage response. Lentivirus
harboring the inducible CAS9 expression cassette or
control empty vector was used to transduce hESCs. The
expression of CAS9 was induced with 2 µg/mL doxycy-
cline (Doxy) treatment for 0, 24 h and 48 h. The relative
levels of the phosphorylation of p53, H2AX, CHK1 were
indicated at the bottom. n = 3. Data are presented as mean
value ± SD. *P < 0.05, **P < 0.01. (B) The expression of
CAS9 induced the number of the γH2AX foci in hESC.
hESCs with CAS9 inducible expression cassette were
plated on chamber slides and treated with or without 2 µg/
mL doxycycline for 3 days. The γH2AX foci were detected
by a confocal microscope. Scale bar, 10 µm. Unpaired t
test. n = 20. Data are presented as mean value ± SD.
***P < 0.001. (C) Detection of DNA DSB damage by
Comet assay in hESCs after various treatments. CTL,
hESCs with empty expression vector treated with 2 µg/mL
doxycycline (Doxy), doxorubicin (Dox), Doxy + Dox,
hESCs with CAS9 inducible expression vector were
treated with 2 µg/mL doxycycline for three days, 0.5
µmol/L Dox for 2 h, 2 µg/mL doxycycline for three days +
0.5µmol/L Dox for 2 h. Unpaired t test. n = 20. Data are
presented as mean value ± SD. ***P < 0.001. (D) CAS9 is
present in both nucleus and cytoplasm. CTL or CAS9,
hESCs with lentiviral empty vector or CAS9 inducible
expression cassette were treated with 2 µg/mL doxycy-
cline for 3 days. Cells were fractionated into nuclear and
cytoplasmic fractions, and examined for the levels of CAS9
as well as nuclear and cytoplasmic proteins histone H3
and α-tubulin. (E) The expression of p53 target genes in
hESCs after the expression of CAS9. CTL, CAS9, hESCs
with CAS9 inducible expression vector were treated with or
without 2 µg/mL doxycycline for 3 days. n = 3. Data are
presented as mean value ± SD. *P < 0.05, **P < 0.01,
***P < 0.001. (F) Cellular proliferation after the expression
of CAS9 in hESCs. n = 3. Data are presented as mean
value ± SD. ***P < 0.001. (G) The impact of CAS9
expression on the pluripotency of hESCs. The pluripotency
makers TRA1-60 and TRA1-81 were analyzed in hESCs
with or without CAS9 expression induced by 2 µg/mL Doxy
for 4 days.
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of Doxy to induce much lower expression of CAS9, we
showed that, at the expression levels much lower than those
of standard lenti-viral transduction, CAS9 could still induce
DNA DSB damage (Fig. 2B). Therefore, CAS9 can induce
DNA DSB damage in mammalian cells independently of
exogenous gRNA.
CAS9 disrupts DNA-PK complex by interacting
with KU86
To elucidate the mechanism how CAS9 induces DNA DSB
damage, we investigated the potential interaction between
CAS9 and the components of DNA repair pathways. We
discovered that CAS9 interacted with KU86, a component of
DNA-PK complex essential for NHEJ pathway (Fig. 4A and
4B). The interaction between CAS9 and KU86 was further
confirmed by proximity ligation assay (Fig. 4C). Using a
series of deletional mutants of CAS9, we found that the PAM
domain of CAS9 was involved in the interaction with KU86
and other domains of CAS9 might interfere with the inter-
action between the PAM domain and KU86 (Fig. 4D). In
further support of this notion, the expression of the PAM
domain of CAS9 reduced the interaction between CAS9 and
KU86 (Fig. 4E). The expression of CAS9 disrupted the
interaction between KU86 with DNA-PKcs or K70, indicating
that the interaction between CAS9 and KU86 inhibited the
formation of DNA-PK complex (Fig. 4F).
The formation of DNA-PK complex at the site of DNA
DSB is required for repairing DNA DSB via NHEJ and
maintaining genomic stability (Davis et al., 2014). Therefore,
we hypothesized that CAS9 could inhibit DNA DSB repair
via NHEJ pathway and induce genomic instability by dis-
rupting the formation of DNA-PK complex. In support of this
notion, the expression of CAS9 in hESCs reduced the effi-
ciency to repair DNA DSB damage via NHEJ pathway
(Fig. 5A), but did not affect the efficiency to repair DNA DSB
damage via HDR pathway (Fig. 5B). In addition, the
expression of CAS9 in hESCs significantly increased the
rate of spontaneous mutation of the HPRT gene in hESCs,
indicating that CAS9 induces genomic instability (Fig. 5C).
Therefore, the expression of CAS9 induces genomic insta-
bility in hESCs.
150 kDa
15 kDa
15 kDa
55 kDa
55 kDa
55 kDa
γH2AX
H2AX
Tubulin
CAS9
Doxy
p53
pp53
γH2AX/H2AX: 1     2.3 2.8
1     1.8 2.4
1     1.8 2.4
1     3.5 4.2
2.5 2.5
3.6 4.5pp53/p53:
pp53/p53:
γH2AX/H2AX:
pS15-p53 55 kDa
p53 55 kDa
??????????? 0 0.5 1 2 2
Tet-CAS9 Lenti-CAS9
CAS9 150 kDa
γH2AX 15 kDa
H2AX 15 kDa
α-Tubulin 55 kDa
A B
0 h 24 h 48 h
Figure 2. The expression of CAS9 in hiPSCs and hESCs promotes DNA DSB damage. (A) The inducible expression of CAS9
promotes DNA DSB damage responses in hiPSCs after 2 µg/mL Doxy treatment. The relative levels of the phosphorylation of p53
and H2AX are indicated at the bottom. Consistent data were obtained from two independent experiments. (B) The impact of
expression levels of CAS9 on DNA DSB damage in hESCs. At the same lentiviral titers, the expression levels of CAS9 in hESCs
transduced by standard lentiviral vector are higher than those transduced by the inducible lentiviral vector after 2 µg/mL Doxy
treatment. Much lower expression levels of CAS9 can also promote DNA DSB damage in hESCs after the treatment with
lower dosages of Doxy. The relative levels of the phosphorylation of p53 and H2AX are indicated at the bottom.
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High fidelity or nuclease-dead CAS9 variants and Cpf1
induce DNA DSB damage
In an attempt to improve the fidelity of CAS9 in gene editing,
recent studies have described CAS9 variants such as
xCAS9 that appear to have higher fidelity (Hu et al., 2018).
However, similarly to CAS9, XCAS9 also interacted with
KU86 and induced DNA DSB damage independently of the
exogenous gRNA (Fig. 5D and 5E). In addition, XCAS9
impaired DNA DSB repair via NHEJ but did not affect the
DNA DSB repair via HDR (Fig. 5A). Therefore, XCAS9 is
also a genome mutator that can promote DNA DSB damage
in the absence of any gRNAs.
Table 1. Primers used in this study.
Sequence (5′-3′)
Primers for cloning
Fuw-teto-CAS9/XCAS9/dCAS9-pgk-
puro Gibson F
TATCGATAAGCTTGATATCGAATTCTCAGGCACCGGGCTTGCGGG
Fuw-teto-CAS9/XCAS9/dCAS9-pgk-
puro Gibson R
ATCCAGCCTCCGCGGCCCCGAATTCGCCACCATGGACAAGAAGTACAGCAT
Fuw-teto-control-pgk-puro F AATTCGCCACCATGGATTACAAAGACGATGACGATAAGTAGA
Fuw-teto-control-pgk-puro R CCGGTCTACTTATCGTCATCGTCTTTGTAATCCATGGTGGCG
plenti-CAS9-pgk-puro Gibson F ACCGACTCTAGAGGATCCGCCACCATGGACAAGAAGTACAGCATCGGCC
plenti-CAS9-pgk-puro Gibson R TCCAGAGGTTGATTGTCGACCTACTTATCGTCATCGTCTT
Fuw-teto-95-pgk-puro Gibson F GACCGATCCAGCCTCCGCGGCCCCGAATTCGCCACCATGGACAGCTTCTTCCACAGACTG
Fuw-teto-95-pgk-puro Gibson R TGGAAAAGGCGCAACCCCAAACCGGTCTACTTATCGTCATCGTCTTTGTAATC
plenti-719-pgk-puro Gibson F GACCGATCCAGCCTCCGCGGCCCCGAATTCGCCACCATGAGCCTGCACGAGCACATT
Fuw-teto-719-pgk-puro Gibson R TGGAAAAGGCGCAACCCCAAACCGGTCTACTTATCGTCATCGTCTTTGTAATC
Fuw-teto-910-pgk-puro Gibson F GACCGATCCAGCCTCCGCGGCCCCGAATTCGCCACCATGGAACTGGATAAGGCCGGCTT
Fuw-teto-910-pgk-puro Gibson R TGGAAAAGGCGCAACCCCAAACCGGTCTACTTATCGTCATCGTCTTTGTAATC
Fuw-teto-1100-pgk-puro Gibson F GACCGATCCAGCCTCCGCGGCCCCGAATTCGCCACCATGGTGCAGACAGGCGGCTTCA
Fuw-teto-1100-pgk-puro Gibson R TGGAAAAGGCGCAACCCCAAACCGGTCTACTTATCGTCATCGTCTTTGTAATC
plenti-control-pgk-puro F GATCCGCCACCATGTACCCATACGACGTCCCAGACTACGCTTAGG
plenti-control-pgk-puro R TCGACCTAAGCGTAGTCTGGGACGTCGTATGGGTACATGGTGGCG
plenti-Ku86-pgk-puro Gibson F GACACCGACTCTAGAGGATCCGCCACCATGTACCCATA
CGACGTCCCAGACTACGCTATGGTGCGGTCGGGGAATAAG
plenti-Ku86-pgk-puro Gibson R TCACAAATTTTGTAATCCAGAGGTTGATTGTCGACGAATTC
CTATATCATGTCCAATAAATCGTCC
Fuw-teto-Cpf1-pgk-puro Gibson F AAGCCCTCGAACTGTGTCATGGTGGCGAATTCGGGGCCGCGGAGGCTGGAT
Fuw-teto-Cpf1-pgk-puro Gibson R AGACGATGACGATAAGTAGACCGGTTTGGGGTTGCGCCTTTTCCA
Primers for RT-qPCR
Puma F ACGACCTCAACGCACAGTACGA
Puma R CCTAATTGGGCTCCATCTCGGG
P21 F ACCTGGAGACTCTCAGGGTCG
P21 R TTAGGGCTTCCTCTTGGAGAAGAT
Perp F TCATCCTGTGCATCTGCTTC
Perp R GGGTTATCGTGAAGCCTGAA
Noxa F ACCAAGCCGGATTTGCGATT
Noxa R ACTTGCACTTGTTCCTCGTGG
β-actin F AGCGAGCATCCCCCAAAGTT
β-actin R GGGCACGAAGGCTCATCATT
RESEARCH ARTICLE Shuxiang Xu et al.
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Mammalian cells might express endogenous gRNA-like
small RNA that could work with CAS9 to induce DNA dam-
age. To test this possibility, we examined the impact of the
expression of dCAS9, which is defective in the nuclease
activity (Gilbert et al., 2013; Maeder et al., 2013), on DNA
DSB damage. Similar to CAS9 and XCAS9, dCAS9 also
interacted with KU86 (Fig. 6A). In addition, the expression of
dCAS9 in hESCs also promoted DNA DSB damage and
genetic mutations at HPRT locus (Fig. 6B and 6C). While the
impact of dCAS9 on DNA damage appeared to be less
dramatic than CAS9, the results demonstrate that CAS9 can
induce DNA damage independent of its nuclease activity.
Similarly to CAS9, Cpf1 also interacted with KU86 and
activated DNA DSB damage (Fig. 6D and 6E).
Previous studies evaluated the genomic stability of cells
after the site-specific gene editing induced by CAS9 + gRNA,
suggesting that the specificity of gRNA and the delivery
method of CAS9/gRNA could be optimized to improve the
fidelity and safety of this gene editing technology (Haa-
paniemi et al., 2018; Ihry et al., 2018; Kosicki et al., 2018).
Our data demonstrate that CAS9 and its high-fidelity variant
XCAS9 are genome mutators by promoting DNA DSB
damage and genetic mutations independently of gRNA. This
intrinsic oncogenic activity of CAS9 is achieved by disrupting
DNA-PK complex, leading to impaired DNA DSB repair via
NHEJ pathway. In addition, it has been well documented that
defects in the DNA-PK function will promote DNA DSB
damage and genetic instability (Davis et al., 2014). There-
fore, our findings raise concerns for the safety of CRISPR/
CAS9 system based human therapy. The development of
CAS9 variants that retain the gene editing activity of wild
type CAS9 but do not disrupt DNA-PK activity might help to
improve the fidelity of gene editing technology and safety of
the CRISPR/CAS9 system.
MATERIALS AND METHODS
Cell lines, lentivirus production and transduction
Human embryonic stem cell line H9 was obtained from
WiCell Research Institute, Inc. and cultured with mTeSR1
medium (STEMCELL, USA). Human fibroblasts were used
between passages 3 to 12. The HEK 293 FT and HEK 293T
cell lines were purchased from Thermo Scientific. Human
fibroblasts and HEK 293 FT were cultured in DMEM (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Hyclone)
and 1% penicillin-streptomycin (Pen/Strep) (Gibco) at 37 °C
with 5% CO2. The lentivirus production and transduction
were performed as we previously described (Kim et al.,
2019). All cell lines were routinely checked for mycoplasma
by a PCR detection kit.
Expression vector construction
To construct vectors that express genes inducibly,
CAS9, XCAS9, dCAS9 or Cpf1 cDNA was cloned into TetO-
Fuw-PGK-Puro vector modified from TetO-Fuw-OSKM vec-
tor (Addgene plasmid 20321) linearized by EcoRI/AgeI
digestion using Gibson Assembly (2× NEBuilder HiFi DNA
Assembly Master Mix) as previously described (Kim et al.,
2019). To generate KU86 and CAS9 deletional mutants,
pLenti-CMV-GFP vector (Addgene 17448) was linearized by
BamHI/SalI digestion and ligated with the PCR products of
KU86 and different domains of CAS9 by Gibson assembly.
The PCR primers were provided in Table 1.
Western blot analysis and Co-immunoprecipitation (Co-
IP)
Cells were extracted for total proteins using lysis buffer
containing Protease and Phosphatase Inhibitor Cocktail
(Cell Signaling Technology CST). For nuclear protein
extraction, nuclear and cytoplasm protein extraction kit
(Thermo Fisher Scientific) was used following the instruction.
Protein was separated on 6%–15% SDS PAGE and trans-
ferred to 0.45 µm nitrocellulose membranes (Merck Millipore
USA), which were blocked with the blocking buffer (5% skim
milk in TBS with 0.05% Tween 20) and incubated with pri-
mary antibodies at 4 °C overnight. The membranes were
Table 2. Antibodies used in this study
Antibody Source and catalog
Anti-γH2AX Cell signaling (9718S, 80312S)
Anti-H2AX Cell signaling (7631S)
Anti-p53 Santa Cruze (sc-126)
Anti-pp53 Cell signaling (9286S)
Anti-CHK1 Cell signaling (2360S)
Anti-pCHK1 Cell signaling (12302S)
Anti-H3 Abcam (ab1971)
Anti-KU86 Santa Cruze (sc-5280), Abcam
(ab119935), Cell signaling
(2753s)
Anti-KU70 Abcam (ab92450)
Anti-DNA PKcs Abcam (ab70250)
Anti-BRCA1 Cell signaling (14823S)
Anti-p-BRCA1 Cell signaling (9009S)
Anti-CHK2 Cell signaling (6334S)
Anti-pCHK2 Cell signaling (2197S)
Anti-CAS9 Cell signaling (14697S), Abcam
(ab189380), Novus Biologicals
(NBP2-52717)
(NBP2-52717)
Anti-β-actin Cell signaling (4970S)
Anti-Flag Thermo Fisher (MA1-91878)
Anti-α-tubulin Santa Cruze (sc-73242)
CAS9 disrupts non-homologous end-joining DNA repair RESEARCH ARTICLE
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Figure 3. The expression of CAS9 in human fibroblasts promotes DNA DSB damage and activates DNA damage response
pathways. (A) The expression of CAS9 in human fibroblasts activates DNA damage responses. The expression of CAS9 was
induced with 2 µg/mL Doxy treatment. The relative levels of phosphorylation of BRCA1, CHK1, CHK2 and p53 are indicated at the
bottom. n = 3. Data are presented as mean value ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. (B) The expression of CAS9 increased the
number of γH2AX foci in human fibroblasts. CTL or CAS9, human fibroblasts with CAS9 inducible expression cassette plated on
chamber slides were treated with or without 2 µg/mL doxycycline for 3 days. The expression of CAS9 and γH2AX foci was revealed
by immunoflourescence analysis. Representative images are shown. Scale bar, 10 µm. Unpaired t test. n = 20. Data are presented as
mean values ± SD. ***P < 0.001. (C) CAS9 induces DNA DSB damage in human fibroblasts. CTL, human fibroblasts with lentiviral
empty vector were treated with 2 µg/mL doxycycline for three days; Doxy, Dox, Doxy + Dox, human fibroblasts with lentiviral CAS9
inducible expression vector were treated with 2 µg/mL doxycycline for 3 days or 0.5 µmol/L Dox for 2 h or 2 µg/mL doxycycline for
three days + 0.5 µmol/L Dox for 2 h, respectively. Representative images are shown. n = 40. Unpaired t test. Data are presented as
mean value ± SD. **P < 0.01.
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incubated with secondary antibodies at room temperature for
1 h and detected with Supersignal West Pico or Dura
exposure buffer (Thermo Fisher Scientific). For Co-IP, the
cells were collected and lysed with IP lysis buffer (Thermo
Fisher Scientific) containing protease inhibitor cocktail
(Thermo Fisher Scientific) on ice for 30 min. After the cen-
trifugation at 12,000 ×g for 20 min at 4 °C, the supernatants
were immunoprecipitated with antibodies followed by incu-
bating with magnetic protein A/G beads (Pierce) for 4 h. For
IP analysis of phosphorylated proteins, cells were collected
in the IP lysis buffer containing Protease and Phosphatase
Inhibitor Cocktail. The antibodies used were provided in
Table 2.
Proximity ligation analysis
hESCs with inducible CAS9 expression vector were plated
on chamber slides and treated with 2 µg/mL doxycycline for
2 days. After the treatment, the cells were washed with PBS
twice and then fixed with 4% paraformaldehyde (PFA) for 15
min at room temperature. After washing with PBS three
times, cells were permeabilized with 0.3% Triton X-100 in
PBS for 10 min at room temperature. Then Duolink® In Situ
Red Starter Kit Mouse/Rabbit (Sigma, DUO92101) was used
to reveal the interaction between CAS9 and KU86 as
instructed by the manufacturer. The antibodies of different
species (rabbit anti-CAS9 antibody, mouse anti-KU86 anti-
body) were used to detect the proteins. DAPI (blue) was
used to stain the nucleus.
Immunofluorescence staining
1 × 103 H9 or fibroblast cells were seeded onto the chamber
slides coated with matrigel (Corning) and treated with 2 µg/
mL doxycycline for 2 days. After the treatment, cells were
washed with PBS twice, and then fixed with 4%
paraformaldehyde (PFA) for 15 min at room temperature.
After washing with PBS three times, cells were permeabi-
lized with 0.3% Triton X-100 in PBS for 10 min, blocked with
2% bovine serum albumin (BSA) in PBS for 1 h at room
temperature, stained with anti-CAS9 antibody (Abcam,
1:100) and anti-γH2AX antibody (CST, 1:100) at 4 °C over-
night, followed by simultaneous incubation with Alexa Fluor
568-conjugated anti-mouse secondary antibody and Alexa
Fluor 488-conjugated anti-rabbit antibody for 1 hr at room
temperature. Slides were mounted using VECTASHIED
solution (Vector) with DAPI. The images were acquired as
previously described (Chen et al., 2018).
Comet assay analysis
Comet assay was carried out as we previously described
(Xiong et al., 2015). Briefly, hESCs or fibroblasts plated on
the matrigel-coated 6-well plates were treated with 2 µg/mL
doxycycline for 2 days, followed with or without the treatment
with 0.5 µmol/L doxorubicin for 4 h. Cells were harvested,
washed with ice-cold PBS twice, resuspended at a density of
105 cells/mL, mixed with agarose at a 1:10 ratio, spread onto
3-well Comet Assay slides, and kept in dark for 15 min at
room temperature. Slides were immersed in chilled lysis
solution for 15 min, washed with chilled TBE buffer three
times and electrophoresed in chilled TBE (Tris-borate-EDTA)
buffer for 15 min at 20 V. Slides were then fixed in 70%
ethanol and dried, and DNA was labeled with Vista Green
DNA Dye diluted with TBE buffer. Images were captured and
analyzed using Image J software.
RNA purification and quantitative PCR analysis
The RNA extraction and qPCR were performed as we pre-
viously described (Kim et al., 2019). The primers used for
qPCR were listed in Table 1.
Cell viability
hESC cells were digested with TripLe (Gibco) to prepare
single cells. 4 × 103 cells/well were plated onto each well of
the 96-well plates with triplicate wells per sample. Cell
Counting Kit (CCK8, DoJindo) was used to evaluate cell
viability according to the manufacturer’s instructions.
cFigure 4. CAS9 interacts with KU86 and disrupts the
formation of DNA-PK. (A and B) Reciprocal immunopre-
cipitation shows the interaction between CAS9 and KU86.
Protein extracts from hESCs expressing CAS9 were
immunoprecipitated with anti-KU86 (A) or anti-CAS9 (B),
and immune precipitates were analyzed for the presence
of KU86 and CAS9. (C) The interaction between CAS9
and KU86 was confirmed by the proximity ligation analysis
(PLA). Cell nucleus were revealed by DAPI (Blue) staining
and the CAS9-KU86 interaction indicated by red color.
Scale bar, 25 µm. Unpaired t test. n = 20. Data are
presented as mean value ± SD. ***P < 0.001. (D) Mapping
the domain of CAS9 involved in the interaction with KU86.
The Flag-tagged deletional mutants of CAS9 expressed in
293FT cells were immunoprecipitated with anti-flag anti-
body. Immune precipitates were analyzed for the presence
of CAS9 mutants and KU86. (E) The expression of
the PAM domain (1100) of CAS9 disrupted the interaction
between CAS9 and KU86. The levels of CAS9, KU86,
PAM in the input and immunoprecipitate were analyzed by
Western blot. The ratio of CAS9 versus KU86 in the
immunoprecipitate is shown at the bottom. (F) CAS9
disrupts the formation of DNA-PK complex. Protein
extracts of cells in the presence and absence of CAS9
and DOX treatment were immunoprecipitated with anti-
KU86 antibody. The levels of KU70, DNA-PKcs and CAS9
in the immunoprecipitate were analyzed. The relative
ratios of DNA-PKcs versus KU86 or KU70 versus KU86
are indicated.
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Detection of spontaneous mutations of the HPRT gene
in hESCs
The detection of spontaneous mutations of the HPRT gene
in hESCs was performed as previously described (Kang
et al., 2002). Briefly, hESCs with empty vector or with CAS9
inducible expression vector were treated with 1× hypoxan-
thine-aminopterin-thymidine (HAT) medium for 5 days to
eliminate hESCs with HPRT mutations. After replating, 2 µg/
mL doxycycline was added to induce the expression of
CAS9 for 24 h, 48 h or 72 h. Cells were harvested and plated
on triplicate 6 wells at a density of 105 cells/well. These
cultures were mock treated or treated with 5 µg/mL
6-thioguanine (6-TG) for 3 days to select for hESCs lacking
functional HPRT. Cultures were incubated for 8–10 days and
colonies fixed with 4% paraformaldehyde (PFA) for 10 min at
RT. After washing with PBS three times, colonies were
visualized by staining with crystal violet. The number of
colonies was counted using the Image J software.
Detection of DNA DSB repair via NEHJ and HDR
pathways
We used the Traffic Light Reporter system to evaluate the
efficiency to repair DNA DSBs via NHEJ and HDR pathways
as previously described (Gomez-Cabello et al., 2013).
Briefly, HEK293FT cells were transduced with Traffic Light
Reporter virus and 5 μg/mL polybrene. After 48 h, cells were
selected with 1 μg/mL puromycin for 3 days. Surviving clone
was picked, expanded and verified with PCR to confirm the
integration of the reporter harboring an I-sce1 site. Reporter
cells were transduced with the control or inducible CAS9
expression lentivirus. 6 × 104 control or cells with inducible
CAS9 expression vector were plated onto the triplicate wells
of 48-well plates. After the induction of the expression of
CAS9, the cells were transduced with I-SceI-T2A-IFP or
control empty lentivirus. Ten days later, cells were collected
and analyzed by flow cytometry. The results were analyzed
by Flowjo software.
Statistical analysis
Any statistical method was used to calculate group variation
was not estimated before experiments. Statistical signifi-
cance was assayed with GraphPad Prism. For comparing
two groups, t-test was used. *P < 0.05, **P < 0.01, ***P <
0.001, ns means non-significant.
b Figure 5. Both CAS9 and XCAS9 impair NHEJ and induce
genetic mutations. (A and B) Expression of CAS9 and XCAS9
impairs NHEJ. Traffic Light Reporter system was established in
293 cells harboring the CAS9 and XCAS9 inducible expression
vectors. After the induction of CAS9 and XCAS9 expression
with 2 µg/mL doxycycline for 3 days (left panel), the efficiency of
NHEJ (mcherry) and HDR (GFP) was analyzed by flow
cytometry (middle panel). Statistic analysis of the efficiency of
NHEJ (left panel of A) and HDR (B) is presented. n = 3. Data
are presented as mean values ± SD. *P < 0.05, **P < 0.01,
***P < 0.001. ns, non-significant. (C) The expression of CAS9 in
hESCs induces genomic mutations at the endogenous HPRT
locus. After hESCs harboring CAS9 inducible expression vector
were selected with HAT medium for 5 days, they were treated
with 2 µg/mL doxycycline for CAS9 expression for various time
periods, and subsequently, treated with 5 µg/mL 6-TG or mock
treated for 4 days. Mutational rate is calculated as the ratio of
colony number in 6-TG treated samples versus untreated
controls. n = 3. Data are presented as mean values ± SD. ***P <
0.001. (D) XCAS9 interacts with KU86. Protein extracts from
293FT cells expressing Flag-tagged CAS9 or XCAS9 were
immunoprecipitated with anti-Flag antibody. The immune pre-
cipitates were analyzed for the presence of CAS9, XCAS9 and
KU86. The relative ratio of KU86 versus CAS9 or XCAS9 is
indicated. (E) The expression of XCAS9 increases the number
of γH2AX foci in hESCs. hESCs harboring XCAS9 inducible
expression vector were treated with or without 2 µg/mL
doxycycline for 3 days. n = 20. Scale bar, 10 µm. Data are
presented as mean values ± SD. ***P < 0.01.
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